KR20170016552A - Compositions for preventing, improving or treating hair loss comprising deoxycholic acid as an active component - Google Patents
Compositions for preventing, improving or treating hair loss comprising deoxycholic acid as an active component Download PDFInfo
- Publication number
- KR20170016552A KR20170016552A KR1020150109534A KR20150109534A KR20170016552A KR 20170016552 A KR20170016552 A KR 20170016552A KR 1020150109534 A KR1020150109534 A KR 1020150109534A KR 20150109534 A KR20150109534 A KR 20150109534A KR 20170016552 A KR20170016552 A KR 20170016552A
- Authority
- KR
- South Korea
- Prior art keywords
- hair
- composition
- hair loss
- present
- deoxycholic acid
- Prior art date
Links
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 230000003676 hair loss Effects 0.000 title claims abstract description 34
- 208000024963 hair loss Diseases 0.000 title claims abstract description 34
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 229960003964 deoxycholic acid Drugs 0.000 title claims abstract description 19
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 title claims abstract description 19
- 230000003779 hair growth Effects 0.000 claims abstract description 20
- 230000012010 growth Effects 0.000 claims abstract description 9
- 230000035755 proliferation Effects 0.000 claims abstract description 6
- 230000003658 preventing hair loss Effects 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 11
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 9
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 229940016667 resveratrol Drugs 0.000 claims description 9
- 235000021283 resveratrol Nutrition 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 210000000442 hair follicle cell Anatomy 0.000 claims description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 5
- 235000013824 polyphenols Nutrition 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 230000001256 tonic effect Effects 0.000 claims description 2
- GVPBXLMJFSPIMB-UHFFFAOYSA-N 2-(diethylamino)-n-(2,4,6-trimethylphenyl)acetamide;[3-(hydroxymethyl)-1-oxido-4-oxoquinoxalin-4-ium-2-yl]methanol;6-methyl-1h-pyrimidine-2,4-dione Chemical compound CC1=CC(=O)NC(=O)N1.C1=CC=C2N([O-])C(CO)=C(CO)[N+](=O)C2=C1.CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GVPBXLMJFSPIMB-UHFFFAOYSA-N 0.000 claims 1
- 235000015927 pasta Nutrition 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 239000007952 growth promoter Substances 0.000 abstract description 4
- 230000003325 follicular Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 210000004209 hair Anatomy 0.000 description 41
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 38
- 229960003604 testosterone Drugs 0.000 description 19
- 231100000360 alopecia Toxicity 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- 210000003780 hair follicle Anatomy 0.000 description 5
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 4
- 229960004039 finasteride Drugs 0.000 description 4
- 229960003632 minoxidil Drugs 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000004631 alopecia areata Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 230000003778 catagen phase Effects 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- KZMACGJDUUWFCH-UHFFFAOYSA-O malvidin Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KZMACGJDUUWFCH-UHFFFAOYSA-O 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000011929 mousse Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical group C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 102100033875 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Human genes 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 101000640851 Homo sapiens 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- PMOWTIHVNWZYFI-WAYWQWQTSA-N cis-2-coumaric acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1O PMOWTIHVNWZYFI-WAYWQWQTSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000003808 decrease of hair loss Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 1
- 235000008466 glycitein Nutrition 0.000 description 1
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000009584 malvidin Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- PMOWTIHVNWZYFI-UHFFFAOYSA-N o-Coumaric acid Natural products OC(=O)C=CC1=CC=CC=C1O PMOWTIHVNWZYFI-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 디옥시콜산(deoxycholic acid)을 유효성분으로 포함하는 탈모의 예방, 개선 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing, ameliorating or treating hair loss comprising deoxycholic acid as an active ingredient.
최근 들어 탈모 증상은 외형적 이미지에 대한 관심 증가로 인해 생긴 가장 큰 고민거리 중 하나이다. 탈모는 보통 40-50대 남성의 고민거리로만 여겨 왔지만, 현재는 20-30대 탈모 환자가 급등하고 있으며, 여성 탈모도 증가하고 있는 추세이다. 이러한 탈모 증상은 현대인들의 식생활 불균형, 유해한 공기, 오염된 식수, 산성비 및 스트레스 등 많은 환경적인 요인에 의해 심해지고 있다. 이에 따라, 탈모 증상을 예방 및 치료하기 위해 많은 연구가 진행 중이다.In recent years, hair loss symptoms are one of the biggest problems caused by increased interest in external images. Hair loss is usually regarded as a distress for men in the 40s and 50s, but hair loss patients in their 20s and 30s are soaring, and female hair loss is also on the rise. These hair loss symptoms are being aggravated by many environmental factors such as dietary imbalance of modern people, harmful air, polluted drinking water, acid rain and stress. Accordingly, many studies are under way to prevent and treat hair loss symptoms.
모발의 주기는 모발을 성장시키는 성장기(anagen), 성장을 종료하고 모구부가 축소하는 시기인 퇴화기(catagen), 모유두가 활동을 멈추고 모발을 두피에 머무르게 하는 시기인 휴지기(talogen) 및 모유두가 활동을 시작하거나 또는 새로운 모발을 발생시켜 오래된 모발을 탈모시키는 시기인 발생기로 나눌 수 있다.The cycle of hair consists of anagen which grows hair, catagen which is the period of termination of growth and reduction of the size of the moles, activity of the talon which stops the activity of the hair and keeps the hair on the scalp, Or a generator that generates new hair to depilate old hair.
성장기(Anagen Stage; 2-7년)는 모발이 성장하는 기간으로, 다시 모발이 모구로부터 모포로 나가려는 모발 생성 단계와, 딱딱한 케라틴이 모낭 안에서 만들어지는 단계로 나누어진다. 모발은 퇴행기까지 자가성장을 계속한다.The Anagen Stage (2-7 years) is the period of hair growth, divided into two phases: a hair growth phase where the hair tries to migrate from the parent hair to the blanket, and a stage where the hard keratin is made in the hair follicle. Hair continues to self-grow until the retrogressive.
퇴행기(Catagen Stage; 2-3주)는 성장기가 끝나고, 모발의 형태를 유지하면서 대사과정이 느려지는 시기로, 이 단계에서는 케라틴을 만들어내지 않는다. 퇴화기는 전체 모발의 1%를 차지한다. 이때 모구부가 수축하여 모유두로 나눠지며, 모낭에 둘러싸여 위쪽으로 올라가고, 세포분열은 정지 상태이다.Catagen Stage (2-3 weeks) is the period when the metabolic process is slowed down at the end of the growing season, maintaining the shape of the hair, and does not produce keratin at this stage. Degenerators account for 1% of total hair. At this time, the moles are contracted and divide into the dermal papilla, surrounded by the hair follicles, and the cell division is stopped.
휴지기(Talogen Stage; 3개월)는 모유두가 위축되고 모낭이 차츰 쪼그라들며, 모근이 위쪽으로 밀려 올라가 빠진다. 모발이 없어지는 시기로서 다음 성장기 단계가 시작될 때까지의 수명은 3-4개월이다.The Talogen Stage (3 months) shrinks the papillary, the hair follicles shrink gradually, and the hair follicles are pushed upwards and fall out. The lifespan of the hair until the next growth phase begins is 3-4 months.
정상인 사람이 성장기 상태의 모발이 많은데 비해 탈모증(Alopecia)인 사람은 휴지기 상태의 모발이 많아 눈으로 보이는 탈모 현상이 나타내게 된다. 탈모가 진행될수록 성장기의 기간이 짧아지고, 이로 인해 모발은 점점 소형화된다. 따라서, 탈모의 치료를 위해서는 휴지기 상태의 모낭이 성장기로 빨리 갈 수 있도록 하고, 짧아진 성장기를 늘려주는 것이 중요하다.A person with normal hair growth has a lot of hair, but a person with alopecia (Alopecia) has a lot of hair in a resting state, so that it shows visible hair loss phenomenon. As hair loss progresses, the period of growth is shortened, and hair becomes smaller and smaller. Therefore, in order to treat hair loss, it is important to let the hair follicle in the dormant state go to the growing stage quickly and to shorten the growth period.
현재 모발 성장 촉진제제로서 FDA에서 승인한 미녹시딜(minoxidil, 경피도포제)과 피나스테리드(finasteride, 경구복용제) 두 종류가 있다. 미녹시딜은 항고혈압용 경구약제로 사용되었으나, 이 약제를 복용한 환자에서 다모증이 나타나는 것이 관찰되어 현재 두피 도포용으로 남성형 탈모증에 사용되고 있다. 미녹시딜은 피리미딘 유도체로 두피의 혈관을 확장시켜 국소적으로 혈류를 증가시키고 모모세포를 활성화시켜 탈모진행을 더디게 하여, 솜털을 자라나게 하는 효과가 있어 현재 탈모치료제로 널리 사용되고 있다. 피나스테리드는 타입 Ⅱ 5α-환원효소(reductase)를 억제함으로써 탈모를 예방하고 모발의 성장을 증진시키는 남성형 안드로겐성 탈모증 치료의 최초의 경구치료제로서 1997년 FDA 승인 후 현재 전 세계 약 260만 명이 사용하고 있다.Currently, there are two types of minoxidil and finasteride approved by the FDA as a hair growth promoting agent. Minoxidil was used as an oral antihypertensive drug, but hirsutism was observed in patients taking this drug, and it is currently being used for alopecia areata for scalp application. Minoxidil is a pyrimidine derivative that is widely used as a therapeutic agent for hair loss because it enlarges the blood vessels of the scalp by locally increasing blood flow and activating the hair cells to slow down the progress of hair loss and to produce fluffy hair. Finasteride is the first oral therapeutic for the treatment of male androgenetic alopecia that prevents hair loss by inhibiting type Ⅱ 5α-reductase and thereby promotes hair growth. Approximately 2.6 million people around the world are currently using this drug after approval by the FDA in 1997 .
그러나, 미녹시딜은 체중증가, 부종, 심장박동 증가, 협심증, 피부염 및 가려움증 등의 부작용이 보고되었고, 피나스테리드의 경우에는 남성 성기능 장애와 같은 부작용이 임상사례로 보고되고 있어, 사용이 제한적이거나 환자들 스스로가 약물에 대한 거부감을 나타내는 문제점이 있다. 이에 따라, 천연소재에서 유래한 안전한 탈모예방 및 발모 촉진 물질에 대한 소비자들의 관심이 높아지는 있고, 이에 대한 연구도 활발히 이루어지고 있는 추세이다.However, minoxidil has been reported to have adverse effects such as weight gain, edema, increased heart rate, angina pectoris, dermatitis and itching, and side effects such as male sexual dysfunction have been reported in the case of pinastelide, There is a problem indicating that the drug has a negative reaction to the drug. Accordingly, consumers are interested in safe hair loss prevention and hair growth promoting substances derived from natural materials, and research is being actively carried out.
본 명세서 전체에 걸쳐 다수의 논문 및 특허문헌이 참조되고 그 인용이 표시되어 있다. 인용된 논문 및 특허문헌의 개시 내용은 그 전체로서 본 명세서에 참조로 삽입되어 본 발명이 속하는 기술 분야의 수준 및 본 발명의 내용이 보다 명확하게 설명된다.Numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated herein by reference in their entirety to better understand the state of the art to which the present invention pertains and the content of the present invention.
본 발명자들은 탈모의 예방, 개선 또는 치료제를 개발하기 위하여 연구 노력하였다. 그 결과, 담즙산 중 하나인 디옥시콜산이 모낭 세포의 성장 및 증식을 촉진시켜 궁극적으로 발모 효과를 나타냄을 확인함으로써, 본 발명을 완성하였다.The present inventors have made efforts to develop preventive, ameliorative or therapeutic agents for hair loss. As a result, it was confirmed that dioxycholate, which is one of bile acids, promotes growth and proliferation of hair follicle cells, ultimately exhibiting hair growth effect, thus completing the present invention.
따라서, 본 발명의 목적은 탈모의 예방, 개선 또는 치료용 약제학적 조성물을 제공하는 데 있다.Accordingly, an object of the present invention is to provide a pharmaceutical composition for preventing, ameliorating or treating hair loss.
본 발명의 다른 목적은 탈모의 예방 또는 개선용 의약외품 조성물을 제공하는 데 있다.Another object of the present invention is to provide a quasi-drug composition for preventing or ameliorating hair loss.
본 발명의 또 다른 목적은 탈모의 예방 또는 개선용 화장료 조성물을 제공하는 데 있다.It is still another object of the present invention to provide a cosmetic composition for preventing or ameliorating hair loss.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명, 청구범위 및 도면에 의해 보다 명확하게 된다.Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.
본 발명의 일 양태에 따르면, 본 발명은 디옥시콜산을 유효성분으로 포함하는 탈모의 예방, 개선 또는 치료용 약제학적 조성물을 제공한다.According to one aspect of the present invention, there is provided a pharmaceutical composition for preventing, ameliorating or treating hair loss comprising deoxycholic acid as an active ingredient.
본 발명의 다른 일 양태에 따르면, 본 발명은 디옥시콜산을 유효성분으로 포함하는 탈모의 예방 또는 개선용 의약외품 조성물을 제공한다.According to another aspect of the present invention, there is provided a quasi-drug composition for preventing or ameliorating hair loss comprising deoxycholic acid as an active ingredient.
본 발명의 다른 일 양태에 따르면, 본 발명은 디옥시콜산을 유효성분으로 포함하는 탈모의 예방 또는 개선용 화장료 조성물을 제공한다.According to another aspect of the present invention, there is provided a cosmetic composition for preventing or ameliorating hair loss comprising deoxycholic acid as an active ingredient.
본 발명자들은 탈모의 예방, 개선 또는 치료제를 개발하기 위하여 연구 노력하였다. 그 결과, 담즙산 중 하나인 디옥시콜산이 모낭 세포의 성장 및 증식을 촉진시켜 궁극적으로 발모 효과를 나타냄을 확인하였다.The present inventors have made efforts to develop preventive, ameliorative or therapeutic agents for hair loss. As a result, it was confirmed that dioxycholate, which is one of bile acids, promotes the growth and proliferation of hair follicle cells and ultimately shows hair growth effect.
본 발명의 유효성분인 디옥시콜산은 C24H40O4의 분자식으로 표현되는 쓸개즙 속에 존재하는 담즙산(bile acid)의 하나로서, 콜산에서 유래하는 대표적인 2차 담즙산이다. 본 명세서에서는 상기 디옥시콜산의 범위에 이의 염도 포함되는 것으로 해석된다.The deoxycortic acid, which is an active ingredient of the present invention, is one of the bile acids present in the bile which is represented by the molecular formula of C 24 H 40 O 4 and is a representative secondary bile acid derived from cholic acid. In the present specification, it is interpreted that the deoxycholic acid also includes a salt thereof.
본 명세서에서 사용된 용어, "탈모"는 두피로부터 모발이 탈락하는 현상 또는 모발이 성기거나 가늘어지는 상태를 의미하는 용어로서, 탈모증과 혼용되어 사용될 수 있는 용어이다. 상기 탈모증에는 남성호르몬성 탈모증(남성형 탈모증), 원형 탈모증, 휴지기 탈모증, 약제성 탈모증, 기계적 탈모증, 피부질환에 수반되는 탈모증 및 반흔성 탈모증이 포함된다. 따라서, 본 명세서에서 사용된 용어 "탈모"는 그 발생의 직ㅇ간접적인 원인을 불문하고 당업계에서 탈모로서 분류되는 모든 증상을 포함하는 의미로서 이해되어야 한다.As used herein, the term "hair loss" refers to a condition in which hair falls off the scalp or a state where the hair becomes thin or tapered, and can be used in combination with alopecia. The alopecia include male hormoneal alopecia (alopecia areata), alopecia areata, resting alopecia, chemical alopecia, mechanical alopecia, alopecia accompanying scleroderma and scaly alopecia. Thus, the term "hair loss" as used herein should be understood as meaning any condition that is classified as hair loss in the art, regardless of the immediate or indirect cause of its occurrence.
본 발명의 일구현예에 따르면, 본 발명의 조성물은 탈모 방지, 육모 또는 발모용이다. 상기 용어, "탈모 방지"란 상술한 바와 같은 탈모 현상을 예방하고 억제하는 것을 의미하고, 용어 "육모(양모)"란 머리카락을 굵고 건강하게 하는 등 성장기에 있는 모발의 수명을 늘려 머리카락이 풍성하게 보이도록 하는 것을 의미하며, 용어 "발모"란 새로운 모발의 생성을 유도하거나 촉진하는 것을 의미한다. 따라서, 본 발명의 조성물은 탈모 방지제, 육모제(양모제) 및/또는 발모제(발모촉진제)로서 이용될 수 있다.According to one embodiment of the present invention, the composition of the present invention is for hair loss prevention, hair growth or hair growth. The term "hair loss prevention" means prevention and suppression of the hair loss phenomenon as described above. The term "hair growth wool" means that the hair is thick and healthy, , And the term "hair growth" means inducing or promoting the generation of new hair. Therefore, the composition of the present invention can be used as an anti-hair restorer, hair restorer (hair restorer) and / or hair growth promoter (hair growth promoter).
본 발명의 조성물은 제품의 형태(약제학적 조성물, 의약외품 조성물 또는 화장료 조성물)에 따라 적절한 형태로 제제화 될 수 있다. 예를 들어, 본 발명의 조성물은 토닉, 스프레이, 크림, 로션, 에어로졸, 오일, 용액, 현탁액, 젤, 연고, 파스타제, 에멀젼, 리니먼트제, 페이스트, 정제, 캡슐제, 산제, 분말제 및 과립제로 구성된 그룹으로부터 선택되는 제형을 가질 수 있다.The composition of the present invention can be formulated in an appropriate form according to the form of the product (pharmaceutical composition, quasi-drug composition or cosmetic composition). For example, the compositions of the present invention may be in the form of tablets, capsules, powders, granules, powders, granules, powders, granules, powders, ≪ / RTI > granules, and granules.
본 발명의 일구현예에 따르면, 본 발명의 조성물은 피부외용제이다.According to one embodiment of the present invention, the composition of the present invention is an external preparation for skin.
본 발명의 조성물은 유효성분으로서 상술한 디옥시콜산 외에 추가 성분을 더 포함할 수 있다.The composition of the present invention may further contain, as an active ingredient, an additional ingredient in addition to the above-mentioned deoxycholic acid.
본 발명의 일구현예에 따르면, 본 발명의 조성물에 추가적으로 포함되는 유효성분은 폴리페놀이다. 본 발명에서 이용 가능한 폴리페놀은, 예를 들어, 레스베라트롤, 프로토카테츄산, 갈산, p-하이드록시벤조산, 카페산, 클로로겐산, 쿠마린산, 페룰산, 시나프산, 페라고니딘, 페오니딘, 델피니딘, 말비딘, 퀘세틴, 미리세틴, 아피게닌, 루테올린, 헤스페레틴, 나린제닌, 에리오딕티올, 다이드제인, 게니스테인, 글리시테인, 카테킨 및 에피카테킨 등이 있다.According to one embodiment of the present invention, the effective ingredient additionally contained in the composition of the present invention is polyphenol. Polyphenols which can be used in the present invention include, for example, resveratrol, protocatechuic acid, gallic acid, p-hydroxybenzoic acid, caffeic acid, chlorogenic acid, coumarinic acid, ferulic acid, cinnamic acid, peragonidine, , Malvidin, quercetin, myristin, apigenin, luteolin, hesperetin, naringenin, eriodic thiol, daidzein, genistein, glycitein, catechin and epicatechin.
보다 구체적인 일구현예에 따르면, 상기 폴리페놀은 레스베라트롤이다.According to one more specific embodiment, the polyphenol is resveratrol.
본 발명의 일구현예에 따르면, 본 발명의 조성물은 디옥시콜산을 0.1-10 중량%로 포함한다.According to one embodiment of the present invention, the composition of the present invention contains 0.1 to 10% by weight of dioxycholic acid.
본 발명의 약제학적 조성물은 약제학적으로 허용되는 담체를 포함한다. 상기 약제학적으로 허용되는 담체는 제제 시에 통상적으로 이용되는 것으로서, 락토오스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산칼슘, 알기네이트, 젤라틴, 규산칼슘, 미세결정성 셀룰로오스, 폴리비닐피롤리돈, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다.The pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier. The pharmaceutically acceptable carriers are those conventionally used in the formulation and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, But are not limited to, polyvinylpyrrolidone, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
본 발명의 약제학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. 적합한 약제학적으로 허용되는 담체 및 제제는 Remington's Pharmaceutical Sciences (19th ed., 1995)에 상세히 기재되어 있다.The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약제학적 조성물은 경구 또는 비경구(예컨대, 경피 투여)로 투여할 수 있다.The pharmaceutical composition of the present invention can be administered orally or parenterally (for example, transdermal administration).
본 발명의 약제학적 조성물의 적합한 투여량은 제제화 방법, 환자의 연령, 체중, 성, 탈모 기간, 탈모 상태, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하며, 보통으로 숙련된 의사는 소망하는 치료 또는 예방에 효과적인 투여량을 용이하게 결정 및 처방할 수 있다.The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, the patient's age, body weight, sex, duration of depilation, hair loss state, administration time, administration route, excretion rate and responsiveness, A skilled physician can readily determine and prescribe dosages effective for the desired treatment or prophylaxis.
본 발명의 약제학적 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화 함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질 중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 산제, 좌제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention may be formulated into a unit dose form by formulating it with a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person skilled in the art to which the present invention belongs Or by intrusion into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, suppositories, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
한편, 약사법에 따르면 의약외품(醫藥外品)은 인체에 대한 작용이 약하거나 인체에 직접 작용하지 아니하며, 기구 또는 기계가 아닌 것과 이와 유사한 것으로 정의되며, 보건복지부 고시에 따르면 탈모의 방지 또는 양모를 목적으로 쓰이는 외용제제는 의약외품으로 분류되고 있다. 또한, 화장품법에 따르면, 화장품은 인체를 청결ㅇ미화하여 매력을 더하고 용모를 밝게 변화시키거나 피부ㅇ모발의 건강을 유지 또는 증진하기 위하여 인체에 사용하는 물품으로서 인체에 대한 작용이 경미한 것으로 정의된다.On the other hand, according to the Pharmaceutical Affairs Law, quasi-drugs are defined as being weak to the human body, not acting directly on the human body, and similar to those not of the apparatus or machine. According to the notification of the Ministry of Health and Welfare, Are classified as quasi-drugs. According to the Cosmetics Act, cosmetics are defined as products that are used in the human body to maintain or enhance the health of the hair, to change the appearance, brighten the appearance, add charm to the body by cleansing the body,
본 발명의 외약외품 또는 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 페이스트형, 무스형, 젤형, 액상, 에멀젼형, 현탁액형, 크림형, 연고형, 시트형, 에어로졸형, 스프레이형 및 리니먼트제 등의 각종 형태의 외용제로서 제형화 될 수 있다.The cosmetic or cosmetic composition of the present invention may be prepared in any form conventionally produced in the art, and examples thereof include pastes, mousses, gels, liquids, emulsions, suspensions, creams, ointments , A sheet type, an aerosol type, a spray type, and a liniment.
본 발명의 일구현예에 따르면, 본 발명의 의약외품 또는 화장료 조성물은 헤어샴푸, 헤어린스, 헤어토닉, 헤어컨디셔너, 헤어에센스, 헤어로션, 헤어영양로션, 헤어크림, 헤어영양크림, 헤어모이스처크림, 헤어마사지크림, 헤어왁스, 헤어 에어로졸, 헤어팩, 헤어비누, 헤어겔, 헤어글레이즈, 헤어무스 또는 헤어스프레이의 제형을 갖는다.According to one embodiment of the present invention, the quasi-drug or cosmetic composition of the present invention can be used for hair shampoo, hair rinse, hair tonic, hair conditioner, hair essence, hair lotion, hair nutrition lotion, hair cream, hair nutrition cream, Hair massage cream, hair wax, hair aerosol, hair pack, hair soap, hair gel, hair glaze, hair mousse or hair spray.
본 발명의 특징 및 이점을 요약하면 다음과 같다:The features and advantages of the present invention are summarized as follows:
(ⅰ) 본 발명은 디옥시콜산을 유효성분으로 포함하는 탈모의 예방, 개선 또는 치료용 조성물을 제공한다.(I) The present invention provides a composition for preventing, ameliorating or treating hair loss comprising deoxycholic acid as an active ingredient.
(ⅱ) 디옥시콜산은 모낭세포의 증식과 성장을 촉진하여 궁극적으로 발모 효과를 나타내므로, 본 발명의 조성물을 탈모 방지제, 육모제 또는 발모제로서 사용할 수 있다.(Ii) Deoxycholic acid promotes the proliferation and growth of hair follicle cells, ultimately exhibiting a hair growth effect, so that the composition of the present invention can be used as an anti-hair restorer, hair restorer, or hair growth promoter.
도 1은 T 군(테스토스테론 10 mg/㎖), TD 군(테스토스테론 10 mg/㎖ + 디옥시콜산 1 mg/㎖) 및 TF 군(테스토스테론 10 mg/㎖ + 피나스테리드 1 mg/㎖)의 탈모 부위의 면적 변화를 보여준다.
도 2는 T 군(테스토스테론 10 mg/㎖), TD 군(테스토스테론 10 mg/㎖ + 디옥시콜산 1 mg/㎖) 및 TF 군(테스토스테론 10 mg/㎖ + 피나스테리드 1 mg/㎖)의 모낭세포의 수를 보여준다.
도 3은 T 군(테스토스테론 10 mg/㎖), TR 군(테스토스테론 10 mg/㎖ + 레스베라트롤 1 mg/㎖), TF 군(테스토스테론10 mg/㎖ + 피나스테리드 1 mg/㎖) 및 TRF 군(테스토스테론 10 mg/㎖ + 레스베라트롤 1 mg/㎖ + 피나스테리드 1 mg/㎖)의 탈모 부위의 면적 변화를 보여준다.Fig. 1 shows the results of the evaluation of the degree of hair loss in the T group (
FIG. 2 is a graph showing the change of the concentration of follicular cells in T group (
FIG. 3 is a graph showing the effect of the testosterone (
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
실시예Example
실험재료 및 실험방법Materials and Experiments
실험재료Experimental material
테스토스테론은 wako pure chemical industry에서 구입하였고, 디옥시콜산( deoxycholic acid), 피나스테리드(finasteride), 레스베라트롤(resveratrol) 및 NMP(N-Methyl-2-pyrrolidone)는 씨그마 알드리치 코리아에서 구입하였다. 에탄올은 OCI(주)에서 구입하였고, 글리세롤은 (주)바이오세상에서 구입하였다.Testosterone was purchased from the wako pure chemical industry and deoxycholic acid, finasteride, resveratrol and NMP (N-Methyl-2-pyrrolidone) were purchased from Sigma-Aldrich Korea. Ethanol was purchased from OCI Co., and glycerol was purchased from Bio World.
동물 준비Animal preparation
B6CBAF1/j 하이브리드 마우스(5주령 수컷, Charles River Japan)를 1주일간 사육실에서 적응시킨 후 6주령부터 실험에 이용하였다.B6CBAF1 / j hybrid mice (5-week-old male, Charles River Japan) were adapted from the breeding room for one week and then used for the experiment from 6 weeks of age.
제제의 준비Preparation of preparation
주사용제로 사용될 용매를 에탄올 15%, NMP 5% 및 PBS 80% 조성으로 만들고, 만들어진 용매에 아래와 같은 농도로 용질을 혼합하여 용액을 제조하였다: T 군(테스토스테론 10 mg/㎖), TD 군(테스토스테론 10 mg/㎖ + 디옥시콜산 1 mg/㎖), TR 군(테스토스테론 10 mg/㎖ + 레스베라트롤 1 mg/㎖), TF 군(테스토스테론 10 mg/㎖ + 피나스테리드 1 mg/㎖), TRF 군(테스토스테론 10 mg/㎖ + 레스베라트롤 1 mg/㎖ + 피나스테리드 1 mg/㎖).(
동물실험Animal experiment
아이소플루레인(isoflurane)을 사용하여 호흡 마취를 하고, 목덜미에 테스토스테론(10 mg/㎖) 용액 100 ㎕를 매일 피하주사 하였다. 2주 후부터 스케일 바(scale bar)와 함께 사진을 찍어 탈모 면적을 정량화 하였다. 테스트 시작 6주 후 마우스를 CO2 인큐베이터를 이용하여 희생시키고, 실험부위 피부를 채취하여 포르말린 용액에 담아 파라핀 블록을 제작하고, 피부를 수평으로 잘라 H&E(Hematoxylin & Eosin) 염색을 한 후, mm2 당 모낭의 개수를 측정하였다.Respiratory anesthesia was performed using isoflurane and 100 μl of testosterone (10 mg / ml) solution was subcutaneously injected into the nape of the neck. After 2 weeks, the area of hair loss was quantified by taking a picture with a scale bar. After the test start 6 weeks mice were sacrificed using a CO 2 incubator and then, test sites harvested skin to produce a paraffin block put in formalin solution and cut the skin in the horizontal H & E (Hematoxylin & Eosin) staining, mm 2 The number of follicular sacs was measured.
실험결과Experiment result
도 1에 나타난 바와 같이, 디옥시콜산 처리군(TD 군)은 테스토스테론만 처리한 군(T 군)에 비하여, 약물처리 후 3주부터 탈모 면적이 현저하기 감소하였고, 4주에는 피나스테리드 처리군(TF군)과 비슷한 효과를 나타내었다(도 1). 또한, 도 2에 나타난 바와 같이, 디옥시콜산 처리군(TD 군)에서 테스토스테론만 처리한 군(T 군)에 비하여, 모낭 세포의 증식 및 성장이 현저하였다(도 2).As shown in FIG. 1, the deoxycortic acid-treated group (TD group) showed significantly less hair loss area at 3 weeks after the drug treatment than the testosterone treated group (T group) TF group) (Fig. 1). In addition, as shown in Fig. 2, proliferation and growth of hair follicle cells were remarkable in the group treated with deoxycholic acid (group TD) compared with the group treated with testosterone alone (group T) (Fig. 2).
도 3에 나타난 바와 같이, 테스토스테론만 처리한 군(T 군)에서는 2주 후에도 탈모 면적이 지속적으로 증가하였지만, 레스베라트롤 처리군(TR 군)과 레스베라트롤과 피나스테리드 병용 처리군(TRF 군)에서는 탈모 면적의 증가폭이 현저히 줄어들었다(도 3).As shown in FIG. 3, in the group treated with testosterone alone (T group), the unhairing area continued to increase even after 2 weeks. In the resveratrol treated group (TR group) and resveratrol and finasteride treated group (TRF group) (Fig. 3).
이상으로 본 발명의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현 예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150109534A KR101868208B1 (en) | 2015-08-03 | 2015-08-03 | Compositions for preventing, improving or treating hair loss comprising deoxycholic acid as an active component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150109534A KR101868208B1 (en) | 2015-08-03 | 2015-08-03 | Compositions for preventing, improving or treating hair loss comprising deoxycholic acid as an active component |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170016552A true KR20170016552A (en) | 2017-02-14 |
| KR101868208B1 KR101868208B1 (en) | 2018-06-18 |
Family
ID=58121031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150109534A KR101868208B1 (en) | 2015-08-03 | 2015-08-03 | Compositions for preventing, improving or treating hair loss comprising deoxycholic acid as an active component |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101868208B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018030560A1 (en) * | 2016-08-11 | 2018-02-15 | 사회복지법인 삼성생명공익재단 | Composition for preventing, improving or treating hair loss comprising deoxycholic acid as active ingredient |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0565010A1 (en) * | 1992-04-10 | 1993-10-13 | Antonio Rizzo | Hair dye and hair growth composition |
| JP2005281280A (en) * | 2004-03-31 | 2005-10-13 | Daicho Kikaku:Kk | Dermatologic preparation |
| KR101431965B1 (en) | 2013-02-26 | 2014-08-19 | 부경대학교 산학협력단 | Composition for preventing hair loss and growing hair comprising Hydroxydihydrobovolide |
| KR101438332B1 (en) | 2013-09-05 | 2014-09-04 | 경희대학교 산학협력단 | Composition for preventing hair loss or promoting hair growth comprising forsythiaside-A |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7618956B2 (en) * | 2005-05-31 | 2009-11-17 | The Gillette Company | Reduction of hair growth |
| JP2007063139A (en) * | 2005-08-29 | 2007-03-15 | Daicho Kikaku:Kk | Preparation for skin |
-
2015
- 2015-08-03 KR KR1020150109534A patent/KR101868208B1/en not_active Application Discontinuation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0565010A1 (en) * | 1992-04-10 | 1993-10-13 | Antonio Rizzo | Hair dye and hair growth composition |
| JP2005281280A (en) * | 2004-03-31 | 2005-10-13 | Daicho Kikaku:Kk | Dermatologic preparation |
| KR101431965B1 (en) | 2013-02-26 | 2014-08-19 | 부경대학교 산학협력단 | Composition for preventing hair loss and growing hair comprising Hydroxydihydrobovolide |
| KR101438332B1 (en) | 2013-09-05 | 2014-09-04 | 경희대학교 산학협력단 | Composition for preventing hair loss or promoting hair growth comprising forsythiaside-A |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018030560A1 (en) * | 2016-08-11 | 2018-02-15 | 사회복지법인 삼성생명공익재단 | Composition for preventing, improving or treating hair loss comprising deoxycholic acid as active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101868208B1 (en) | 2018-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104000752B (en) | Ginger extract for stem cell protection | |
| KR100992565B1 (en) | Topical preparations for hair growth | |
| KR20140115400A (en) | Composition of scalp care for prevention of depilation and improvement of hair growth comprising Rhus javanica L. Extracts | |
| CN107530258B (en) | Composition for promoting hair growth or hair restoration and for anti-inflammation | |
| CA2844142A1 (en) | Method for enhancing the growth and fullness of hair | |
| CN111936149B (en) | Pharmaceutical or cosmetic composition for preventing or treating hair loss or promoting hair growth | |
| KR101698922B1 (en) | Composition for promoting hair growth and restoration | |
| KR101733065B1 (en) | Composition comprising Decanal or as active ingredients for preventing hair loss or stimulating hair growth | |
| KR102675966B1 (en) | Composition for preventing hair loss and promoting hair growth | |
| KR101868208B1 (en) | Compositions for preventing, improving or treating hair loss comprising deoxycholic acid as an active component | |
| EP3511006B1 (en) | Composition for preventing, improving or treating hair loss comprising deoxycholic acid as active ingredient | |
| KR20110112765A (en) | Composition for preventing hair loss or promoting hair generation | |
| KR20180094820A (en) | Composition for prevention of losing hair or promotion of growing hair comprising bean extract | |
| KR101588841B1 (en) | Composition for Preventing or Treating Hair Loss or Stimulating Hair Sprouting or Hair Growth Comprising Ocimene as Active Ingredients | |
| KR20120090017A (en) | Composition for preventing hair loss or promoting hair generation | |
| KR20210131598A (en) | Composition for preventing hair loss or promoting hair growth, comprising Camellia japonica pericarp extract as an active ingredient | |
| CN112057463A (en) | Application of cowherb seed flavonoid glycoside in preventing alopecia and promoting hair growth | |
| WO2016060298A1 (en) | Composition containing material for regulating expression of abh antigens | |
| KR101587612B1 (en) | Composition for Preventing or Treating Hair Loss or Stimulating Hair Sprouting or Hair Growth Comprising Pinocarveol as Active Ingredients | |
| KR102343372B1 (en) | Pharmaceutical composition for preventing or treating alopecia | |
| JPH01135711A (en) | Hair tonic | |
| WO2022158809A1 (en) | Composition, for promoting hair growth and preventing alopecia, comprising atraric acid | |
| IT201600120528A1 (en) | Composition containing bioavailable glutathione and oleuropein to prevent hair loss or promote hair growth | |
| KR20230094217A (en) | Composition for preventing hair loss and promoting hair growth comprising Luteolin-7-glucoside | |
| KR102000935B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing 5-hydroxytryptophan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| R401 | Registration of restoration |